242 related articles for article (PubMed ID: 30849944)
1. Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
Kumar N; Zhao D; Bhaumik D; Sethi A; Gann PH
BMC Cancer; 2019 Mar; 19(1):215. PubMed ID: 30849944
[TBL] [Abstract][Full Text] [Related]
2. Quantification of subtype purity in Luminal A breast cancer predicts clinical characteristics and survival.
Kumar N; Gann PH; McGregor SM; Sethi A
Breast Cancer Res Treat; 2023 Jul; 200(2):225-235. PubMed ID: 37209182
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.
Caan BJ; Sweeney C; Habel LA; Kwan ML; Kroenke CH; Weltzien EK; Quesenberry CP; Castillo A; Factor RE; Kushi LH; Bernard PS
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):725-34. PubMed ID: 24521998
[TBL] [Abstract][Full Text] [Related]
4. Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
Bustamante Eduardo M; Popovici V; Imboden S; Aebi S; Ballabio N; Altermatt HJ; Günthert A; Jaggi R
BMC Cancer; 2019 Jun; 19(1):549. PubMed ID: 31174485
[TBL] [Abstract][Full Text] [Related]
5. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
[TBL] [Abstract][Full Text] [Related]
6. Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer.
Cespedes Feliciano EM; Kwan ML; Kushi LH; Chen WY; Weltzien EK; Castillo AL; Sweeney C; Bernard PS; Caan BJ
Cancer; 2017 Jul; 123(13):2535-2542. PubMed ID: 28295245
[TBL] [Abstract][Full Text] [Related]
7. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
9. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.
Sweeney C; Bernard PS; Factor RE; Kwan ML; Habel LA; Quesenberry CP; Shakespear K; Weltzien EK; Stijleman IJ; Davis CA; Ebbert MT; Castillo A; Kushi LH; Caan BJ
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):714-24. PubMed ID: 24521995
[TBL] [Abstract][Full Text] [Related]
11. PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
Wang L; Li Q; Aushev VN; Neugut AI; Santella RM; Teitelbaum S; Chen J
Breast Cancer; 2021 Nov; 28(6):1235-1242. PubMed ID: 34003448
[TBL] [Abstract][Full Text] [Related]
12. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
[TBL] [Abstract][Full Text] [Related]
13. TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays.
Lin CH; Chen IC; Huang CS; Hu FC; Kuo WH; Kuo KT; Wang CC; Wu PF; Chang DY; Wang MY; Chang CH; Chen WW; Lu YS; Cheng AL
Sci Rep; 2015 Dec; 5():17879. PubMed ID: 26671300
[TBL] [Abstract][Full Text] [Related]
14. Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers.
Tishchenko I; Milioli HH; Riveros C; Moscato P
PLoS One; 2016; 11(6):e0158259. PubMed ID: 27341628
[TBL] [Abstract][Full Text] [Related]
15. The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.
Milioli HH; Vimieiro R; Riveros C; Tishchenko I; Berretta R; Moscato P
PLoS One; 2015; 10(7):e0129711. PubMed ID: 26132585
[TBL] [Abstract][Full Text] [Related]
16. A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival.
Jaber MI; Song B; Taylor C; Vaske CJ; Benz SC; Rabizadeh S; Soon-Shiong P; Szeto CW
Breast Cancer Res; 2020 Jan; 22(1):12. PubMed ID: 31992350
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis.
Schettini F; Martínez-Sáez O; Falato C; De Santo I; Conte B; Garcia-Fructuoso I; Gomez-Bravo R; Seguí E; Chic N; Brasó-Maristany F; Paré L; Vidal M; Adamo B; Muñoz M; Pascual T; Ciruelos E; Perou CM; Carey LA; Prat A
ESMO Open; 2023 Jun; 8(3):101214. PubMed ID: 37075698
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer.
Arora A; Abdel-Fatah TM; Agarwal D; Doherty R; Moseley PM; Aleskandarany MA; Green AR; Ball G; Alshareeda AT; Rakha EA; Chan SY; Ellis IO; Madhusudan S
Mol Cancer Ther; 2015 Apr; 14(4):1057-65. PubMed ID: 25673821
[TBL] [Abstract][Full Text] [Related]
19. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
20. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]